A reassessment of triazolam

Anthony Kales, Alexandros N. Vgontzas, Edward O. Bixler

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Concern over the safety of triazolam is reflected in the actions taken against the drug world-wide by many drug regulatory agencies, ranging from restrictions in duration of use and dosage to banning of the drug. There is extensive scientific literature documenting that triazolam produces frequent and severe psychiatric adverse events: during drug administration these include memory impairment/amnesia and other cognitive impairments and daytime anxiety states and early morning insomnia; following drug withdrawal there can be a marked worsening of sleep (rebound insomnia). It is difficult to improve triazolam's benefit-to-risk ratio either by lowering the dose or by short and intermittent use. The 0.5 mg and 1.0 mg doses of triazolam are effective, but produce severe psychiatric adverse events while the 0.25 mg dose has limited efficacy while still being associated with frequent adverse events. Moreover, many of triazolam's adverse events are associated with the first (or first several) doses used, and rebound insomnia often occurs on withdrawal even after only one night of use.

Original languageEnglish (US)
Pages (from-to)7-27
Number of pages21
JournalInternational Journal of Risk and Safety in Medicine
Volume9
Issue number1
DOIs
StatePublished - 1996

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'A reassessment of triazolam'. Together they form a unique fingerprint.

Cite this